Bailard Inc. Takes $112,000 Position in MannKind Co. (NASDAQ:MNKD)

Bailard Inc. acquired a new position in MannKind Co. (NASDAQ:MNKD) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 30,800 shares of the biopharmaceutical company’s stock, valued at approximately $112,000.

Other institutional investors also recently bought and sold shares of the company. Qube Research & Technologies Ltd grew its position in shares of MannKind by 41.8% during the 3rd quarter. Qube Research & Technologies Ltd now owns 559,769 shares of the biopharmaceutical company’s stock worth $2,312,000 after buying an additional 165,039 shares in the last quarter. GSA Capital Partners LLP bought a new stake in shares of MannKind in the 3rd quarter valued at about $673,000. Invesco Ltd. lifted its position in shares of MannKind by 1.6% in the 3rd quarter. Invesco Ltd. now owns 1,621,765 shares of the biopharmaceutical company’s stock worth $6,698,000 after purchasing an additional 25,319 shares during the period. Jump Financial LLC boosted its stake in shares of MannKind by 730.2% during the third quarter. Jump Financial LLC now owns 138,810 shares of the biopharmaceutical company’s stock valued at $573,000 after purchasing an additional 122,090 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in MannKind by 4.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,036,411 shares of the biopharmaceutical company’s stock valued at $8,410,000 after buying an additional 81,742 shares during the period. 49.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

MNKD has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and issued a $7.50 price target on shares of MannKind in a report on Thursday, January 4th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $6.50 target price on shares of MannKind in a research note on Friday, March 15th. Finally, Wedbush reissued an “outperform” rating and set a $10.00 price target on shares of MannKind in a research report on Wednesday, February 28th.

MannKind Trading Up 0.7 %

Shares of MNKD opened at $4.26 on Tuesday. MannKind Co. has a 12 month low of $3.17 and a 12 month high of $5.75. The stock has a fifty day moving average price of $4.35 and a 200-day moving average price of $3.91.

MannKind (NASDAQ:MNKD) last released its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.02. The business had revenue of $58.47 million during the quarter, compared to analysts’ expectations of $52.36 million. As a group, analysts forecast that MannKind Co. will post 0.1 earnings per share for the current year.

MannKind Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.